Imperial College London TELE-ACS Clinical Trial Results, Using SHL Telemedicine’s SmartHeart® Technology, to Be Presented at ACC 24
01 February 2024 - 6:30PM
Business Wire
The selection of the TELE-ACS trial results for presentation at
ACC 24 highlights the pioneering achievements of Imperial College
London and SHL in advancing the field of telemedicine
SHL Telemedicine Ltd. (NASDAQ: SHLT, SIX: SHLTN;) ("SHL" or the
"Company"), a leading provider and developer of advanced personal
telemedicine solutions, is excited to announce that the full
results of the Imperial College London TELE-ACS clinical trial have
been selected for presentation at the prestigious American College
of Cardiology's 24th Annual Scientific Session & Expo
Late-Breaking Clinical Trials Sessions (ACC 24 LBCT) in
Atlanta.
The full results of the TELE-ACS trial, led by Dr. Ramzi Khamis
and Nasser S Alshahrani, will be presented on April 6, 2024, in
session 403-16, titled: “Remote Acute Assessment Of Patients With
High Cardiovascular Risk Post-Acute Coronary Syndrome”. The
TELE-ACS trial is a pivotal study that marks a significant
milestone in telemedicine and cardiovascular care. Accepted for
presentation at the prestigious ACC 24 conference, this clinical
trial explores the effectiveness of remote assessment in patients
with high cardiovascular risk following an acute coronary syndrome,
focusing on the application of SHL's SmartHeart® 12-lead ECG
technology for monitoring of post-MI (heart attack) patients at
home.
Erez Nachtomy, CEO of SHL Telemedicine, commented: “We would
like to congratulate the team at Imperial College London on the
acceptance of the TELE-ACS trial results for presentation at ACC
24. This achievement is a testament to the researchers and their
rigorous effort to conduct this groundbreaking work. We very much
look forward to seeing the presentation at ACC 24 which will share
the embargoed full trial results with the global cardiology
community.”
ACC 24 Participants are invited to add the session to their
itinerary using the following link:
https://www.abstractsonline.com/pp8/#!/10973/presentation/22832
About SHL Telemedicine
SHL Telemedicine is engaged in developing and marketing personal
telemedicine systems and the provision of medical call center
services, with a focus on cardiovascular and related diseases, to
end users and to the healthcare community. SHL Telemedicine offers
its services and personal telemedicine devices to subscribers
utilizing telephonic and Internet communication technology. SHL is
listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885,
Security No.: 1128957) and on the Nasdaq Stock Exchange (SHLT,
ISIN: US78423T2006, CUSIP: 78423T200).
For more information, please visit our website at
www.shl-telemedicine.com.
Forward-Looking Statements
Some of the information contained in this press release contains
forward-looking statements. Readers are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, and that actual results may
differ materially from those in the forward-looking statements as a
result of various factors. SHL Telemedicine undertakes no
obligation to publicly update or revise any forward-looking
statements
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240131123982/en/
Fabienne Farner, IRF, Phone : +41 43 244 81 42,
farner@irf-reputation.ch
SHL Telemedicine (NASDAQ:SHLT)
Historical Stock Chart
From May 2024 to Jun 2024
SHL Telemedicine (NASDAQ:SHLT)
Historical Stock Chart
From Jun 2023 to Jun 2024